ArticleJournal of translational medicine2025
HDAC2-mediated chromatin remodeling drives hepatocellular carcinoma progression: an integrative analysis of computational pathology and multi-transcriptomics.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- DUSP5 contributes to platinum resistance in ovarian cancer: single-cell discovery and functional validation.Frontiers in pharmacology · 2026Article
- Functional Interpretation of Recurrent Genetic Variants in Hepatocellular Carcinoma: Molecular Consequences and Clinical Relevance.Human mutation · 2026Review
- Network-driven prioritization and functional phenotyping nominate TTC23 as a biomarker-informed target in chlorpromazine repurposing for glioblastoma.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) is the most common primary liver cancer, characterized by high heterogeneity and poor prognosis. Chromatin remodeling regulates chromatin structure and function, and its dysregulation promotes tumor progression. Histone deacetylase 2 (HDAC2) is a key regulator involved in this process. This study links clinicopathological features with molecular mechanisms to elucidate the role of the chromatin-remodeling factor HDAC2 in hepatocellular carcinoma.
methodBased on whole-slide images (WSIs) from TCGA-LIHC, pathological features were extracted by combining ResNet-50 and CellProfiler to build a prognostic model. SHAP was subsequently applied to interpret the most influential predictive features. Through integrative multi-omics analysis, HDAC2 was identified as a core gene, and its association with malignant phenotypes was validated using the Human Protein Atlas (HPA), bulk transcriptomic data, and single-cell datasets. Malignant cells were further identified with inferCNVpy, while CellChat and Vector were used to characterize intercellular communication and developmental trajectories. Finally, spatial transcriptomics integrated with the Spotlight and MISTy algorithms revealed the spatial distribution of HDAC2 and its interactions within the tumor microenvironment. The pro-tumor capability of HDAC2 was verified by both cell-based assays and nude mouse tumorigenicity experiments.
resultsFrom WSIs, 630 features were extracted with CellProfiler and 2,048 with ResNet-50. the top nine prognostic features were used to build a Lasso + GBM model selected from 101 machine learning algorithm combinations. SHAP analysis revealed the contribution of each feature. Correlation analysis with a curated chromatin remodeling gene set identified 49 genes significantly associated with these 9 features. For HDAC2, integrative analyses across bulk, single-cell, and spatial transcriptomics revealed its biological roles and underlying mechanisms. ROC curve analysis confirmed strong predictive performance, with average AUCs of 0.84 and 0.77 in the training and validation sets, respectively. HDAC2 knockdown reduced IL-1β/IL-6/TNF-α transcripts, lowered colony formation by ~ 55%, curbed invasion/migration by ~ 30–50% (P < 0.001), and trimmed xenograft weight by ~ 35% (P < 0.01), confirming that HDAC2 drives proliferation, motility and in-vivo tumorigenicity.
conclusionHDAC2 drives hepatocellular carcinoma (HCC) progression by strengthening intercellular communication and forming a spatially organized oncogenic axis. Further analyses indicate that HDAC2-high cells can be regarded as differentiation origin points of the tumor and are significantly associated with poor prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.